Kissei’s Tavalisse Gains Approval in South Korea for Chronic ITP

Kissei Pharmaceutical Co ( (JP:4547) ) has issued an update.

Kissei Pharmaceutical Co., Ltd. announced that its partner, JW Pharmaceutical Corporation, has received marketing authorization in South Korea for Tavalisse, an oral spleen tyrosine kinase inhibitor, for treating thrombocytopenia in adult patients with chronic ITP. This approval marks a significant expansion in Kissei’s market presence, providing a new treatment option for ITP patients in Korea, and potentially strengthening the company’s position in the pharmaceutical market.

More about Kissei Pharmaceutical Co

Kissei Pharmaceutical Co., Ltd. is a leading company in the pharmaceutical industry, headquartered in Matsumoto, Nagano, Japan. The company focuses on developing and commercializing innovative drugs, particularly in areas such as chronic idiopathic thrombocytopenic purpura (ITP). Kissei has partnerships for drug development and commercialization across various regions, including collaboration with JW Pharmaceutical Corporation in South Korea.

YTD Price Performance: -4.64%

Average Trading Volume: 100

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: $1.05B

Find detailed analytics on 4547 stock on TipRanks’ Stock Analysis page.